메뉴 건너뛰기




Volumn 17, Issue 12, 2008, Pages 1817-1828

Discontinued drugs in 2007: Cardiovascular drugs

Author keywords

AC 2592; AZD 6610; AZD 7009; AZD 8677; AZD 9684; Cardio Vascu Grow; CETi 1; CP 778875; CTI 01; LXR 623; LY 518674; PF 3052334; PF 3491165; PF 807925; Pioglitazone HCl + TAK 536; YM 758

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 7 [1 (4 FLUOROPHENYL) 4 ISOPROPYL 3 (4 METHYLBENZYLCARBAMOYL) 5 PYRAZOLYL] 3,5 DIHYDROXYHEPTANOIC ACID; AC 2592; ANGIOGENIC FACTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AR H 050642; AZD 4619; AZD 6610; AZD 6877; AZD 8677; AZD 9684; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CP 778875; CTI 01; CVBT 141A; CVBT 141H; FENOFIBRATE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIVER X RECEPTOR AGONIST; LXR 623; PEPTIDE VACCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PF 3491165; PF 807925; PIOGLITAZONE; PYRUVIC ACID DERIVATIVE; TAK 536; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG; YM 758;

EID: 58149400627     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802465992     Document Type: Review
Times cited : (6)

References (11)
  • 1
    • 0033552883 scopus 로고    scopus 로고
    • Atherosclerosis - An inflammatory disease
    • DOI 10.1056/NEJM199901143400207
    • Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126 (Pubitemid 29054847)
    • (1999) New England Journal of Medicine , vol.340 , Issue.2 , pp. 115-126
    • Ross, R.1
  • 2
    • 37049023446 scopus 로고    scopus 로고
    • La pollution atmospherique: Un facteur de risque de maladie cardiovasculaire
    • DOI 10.1684/stv.2007.0200
    • Ruidavets JB. Atmospheric pollution: a cardiovascular risk factor. Sang Thrombose Vaisseaux 2007;19 (9):487-491 (Pubitemid 350246942)
    • (2007) Sang Thrombose Vaisseaux , vol.19 , Issue.9 , pp. 487-491
    • Ruidavets, J.B.1    Ferrieres, J.2
  • 3
    • 67649345538 scopus 로고    scopus 로고
    • Available from: (last accessed 24 September 2008) This report provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders
    • Available from: http://www.urchpublishing. com/news/aug2007.html (last accessed 24 September 2008) • This report provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders.
  • 4
    • 4344645978 scopus 로고    scopus 로고
    • Can the pharmaceutical industry reduce attrition rates?
    • This article deals with the fiscal pressures that face the pharmaceutical industry from the perspective of R&D
    • Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-716 •• This article deals with the fiscal pressures that face the pharmaceutical industry from the perspective of R&D.
    • (2004) Nat Rev Drug Discov , vol.3 , pp. 711-716
    • Kola, I.1    Landis, J.2
  • 5
    • 67649329280 scopus 로고    scopus 로고
    • Informa UK Plc. Available from: Last accessed 2008 September
    • The Pharmaprojects Database, Informa UK Plc. Available from: http://www.pharmaprojects.com [Last accessed 2008 September]
  • 6
    • 0032562232 scopus 로고    scopus 로고
    • Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
    • Schumacher B, Pecher P, Von Specht BU, Stegmann TH. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650 (Pubitemid 28090957)
    • (1998) Circulation , vol.97 , Issue.7 , pp. 645-650
    • Schumacher, B.1    Peecher, P.2    Von Specht, B.U.3    Stegmann, T.4
  • 9
    • 67649329279 scopus 로고    scopus 로고
    • Available from: last accessed 24 September 2008
    • Available from: http://www.scienceblog.com/ community/older/1999/B/ 199901692.html (last accessed 24 September 2008)
  • 10
    • 12344338322 scopus 로고    scopus 로고
    • AZD7009 - a new atrial antifibrillatory compound that blocks recombinant hNav1.5 and potassium channels [abstract P2885] [plus poster]
    • Paulsson F, Jacobson I, Carlsson L. AZD7009 - a new atrial antifibrillatory compound that blocks recombinant hNav1.5 and potassium channels [abstract P2885] [plus poster]. Eur Heart J 2004;25 (Abstr. Suppl):479
    • (2004) Eur Heart J , vol.25 , Issue.ABSTR. SUPPL. , pp. 479
    • Paulsson, F.1    Jacobson, I.2    Carlsson, L.3
  • 11
    • 33750492125 scopus 로고    scopus 로고
    • AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit [abstract P2939] [plus poster]
    • Carlsson L, Duker G, Linhardt G. AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit [abstract P2939] [plus poster]. Eur Heart J 2004;25 (Abstr. Suppl):492
    • (2004) Eur Heart J , vol.25 , Issue.ABSTR. SUPPL. , pp. 492
    • Carlsson, L.1    Duker, G.2    Linhardt, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.